Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RENB Renovaro Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: RENB
Price (delayed)
$0.2962
Market cap
$50.98M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.32
Enterprise value
$57.09M
enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and
Highlights
The company's EPS has surged by 72% YoY and by 63% QoQ
Renovaro Biosciences's net income has increased by 47% from the previous quarter and by 30% YoY
The equity has declined by 34% year-on-year but it has grown by 8% since the previous quarter
The debt has declined by 18% year-on-year but it has increased by 10% since the previous quarter
Key stats
What are the main financial stats of RENB
Market
Valuations
Earnings
Shares outstanding
172.12M
Market cap
$50.98M
Enterprise value
$57.09M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.53
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$79.15M
Net income
-$67.01M
EBIT
-$66.21M
EBITDA
-$66.08M
Free cash flow
-$8.5M
Per share
Balance sheet
Liquidity
EPS
-$0.32
EPS diluted
-$0.32
Free cash flow per share
-$0.05
Book value per share
$0.56
Revenue per share
$0
TBVPS
$0.03
Total assets
$117.73M
Total liabilities
$29.34M
Debt
$7.03M
Equity
$88.39M
Working capital
-$25.17M
Debt to equity
0.08
Current ratio
0.13
Quick ratio
0.09
Net debt/EBITDA
-0.09
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-52.1%
Return on equity
-66.9%
Return on invested capital
N/A
Return on capital employed
-74.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RENB stock price
How has the Renovaro Biosciences stock price performed over time
Intraday
2.85%
1 week
-5.88%
1 month
-11.82%
1 year
-79.57%
YTD
-64.55%
QTD
-45.47%
Financial performance
How have Renovaro Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$79.15M
Net income
-$67.01M
Gross margin
N/A
Net margin
N/A
Renovaro Biosciences's net income has increased by 47% from the previous quarter and by 30% YoY
RENB's operating income is up by 37% QoQ and by 10% YoY
Price vs fundamentals
How does RENB's price correlate with its fundamentals
Growth
What is Renovaro Biosciences's growth rate over time
Valuation
What is Renovaro Biosciences stock price valuation
P/E
N/A
P/B
0.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 72% YoY and by 63% QoQ
The stock's P/B is 71% below its 5-year quarterly average of 1.8 and 59% below its last 4 quarters average of 1.3
The equity has declined by 34% year-on-year but it has grown by 8% since the previous quarter
Efficiency
How efficient is Renovaro Biosciences business performance
RENB's ROE has soared by 53% year-on-year and by 41% since the previous quarter
The ROA has soared by 52% YoY and by 41% from the previous quarter
Dividends
What is RENB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RENB.
Financial health
How did Renovaro Biosciences financials performed over time
The current ratio has soared by 117% from the previous quarter and by 117% YoY
RENB's total assets is down by 34% YoY but it is up by 6% QoQ
The debt is 92% smaller than the equity
The equity has declined by 34% year-on-year but it has grown by 8% since the previous quarter
The debt to equity has increased by 33% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.